For the CoviCell SkinPatch test the inventors already generated human cell lines stably producing the antigenic SARS-CoV-2 proteins, purified the recombinant antigenic proteins, developed a formulation for skin surface applications, performed in vivo animal toxicology experiments to show the harmless nature of the applied reagents, and performed initial proof-of-concept studies.
The CoviCell skin patch contains a formulated version of recombinant antigenic SARS-CoV-2 virus proteins, applied to the surface of the skin.
When the antigens are recognized by the SARS-CoV-2 specific memory cells, a local skin inflammation is generated. A skin reaction occurs within 24-72 hours, and the local inflammation reflects the protective cellular immunity.
